

11 September 2026

Dear Shareholders,

GENERAL MEETING – NOTICE AND PROXY FORM

Hamelin Gold Limited's (**Hamelin Gold or the Company**) General Meeting is scheduled to be held at Suite 2, 1 Alvan Street, Subiaco, Western Australia on Monday 12 October 2026 at 8.30am (AWST) (**Meeting**).

In accordance with the *Corporations Amendments (Meetings and Documents) Act 2022 (Cth)* which came into effect on 1 April 2022, the Company will not be sending physical copies of the Notice of Meeting, and accompanying Explanatory Memorandum (**Meeting Materials**), to shareholders unless they have made a valid election to receive documents in physical copy.

Instead, a copy of the Meeting Materials will be available electronically under the "ASX announcements" section of the Company's website at www.hamelingold.com.au/investors/.

As you have not elected to receive notices by email, a copy of your personalised proxy form is enclosed for your convenience.

The Directors **strongly encourage all Shareholders to lodge their directed proxy votes prior to the Meeting and appoint the Chair as their proxy** in accordance with the instructions set out in the proxy form. All voting at the Meeting will be conducted by poll.

If Shareholders do not attend the Meeting in person, they will be able to participate by:

- (a) voting prior to the Meeting by lodging the enclosed proxy form attached to the Notice of Meeting by no later than 8.30am (AWST) on 10 October 2026, as per the instructions on the proxy form; and
- (b) lodging questions in advance of the Meeting by emailing the questions to the Chairman at contact@hamelingold.com.au by no later than 10 October 2026.

If you have any difficulties obtaining a copy of the Meeting Materials, please contact the Company Secretary on (08) 9486 9455.

Hamelin Gold shareholders who wish to update their details to be able to receive communications and notices electronically can do so by visiting the Company's share registry website at <https://investor.automic.com.au> and registering an account.

Sincerely,



Peter Bewick
Managing Director

HAMELIN GOLD LIMITED
ACN 650 439 580
NOTICE OF GENERAL MEETING

Notice is given that the Meeting will be held at:

TIME: 8.30AM (WST)

DATE: Monday, 12 October 2026

PLACE: Suite 2, 1 Alvan Street, Subiaco WA 6008

The business of the Meeting affects your shareholding and your vote is important.

This Notice should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers prior to voting.

The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Regulations 2001 (Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders at 5:00PM (WST) on 10 October 2026.

This page has been left blank intentionally.

AGENDA

1. RESOLUTION 1 – RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES – LISTING RULE 7.1

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 29,745,535 Placement Shares on the terms and conditions set out in the Explanatory Statement.”

A voting exclusion statement applies to this Resolution. Please see below.

2. RESOLUTION 2 – RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES – LISTING RULE 7.1A

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 19,830,357 Placement Shares on the terms and conditions set out in the Explanatory Statement.”

A voting exclusion statement applies to this Resolution. Please see below.

3. RESOLUTION 3 – APPROVAL OF ISSUE OF LEAD MANAGER OPTIONS

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, for the purposes of Listing Rule 7.1 and for all other purposes, Shareholders approve the issue of 1,000,000 Lead Manager Options on the terms and conditions set out in the Explanatory Statement.”

A voting exclusion statement applies to this Resolution. Please see below.

4. RESOLUTION 4 – APPROVAL FOR DIRECTOR TO PARTICIPATE IN PLACEMENT – WILL ROBINSON

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, for the purposes of section 195(4) and section 208 of the Corporations Act, Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue up to 300,000 Placement Shares to Will Robinson (or his nominee) on the terms and conditions set out in the Explanatory Statement.”

A voting exclusion statement and voting prohibition statement apply to this Resolution. Please see below.

5. RESOLUTION 5 – APPROVAL FOR DIRECTOR TO PARTICIPATE IN PLACEMENT – PHILIP CRUTCHFIELD

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, for the purposes of section 195(4) and section 208 of the Corporations Act, Listing Rule 10.11 and for all other purposes, approval is given for the Company to

issue up to 812,500 Placement Shares to Philip Crutchfield (or his nominee) on the terms and conditions set out in the Explanatory Statement.”

A voting exclusion statement and voting prohibition statement apply to this Resolution. Please see below.

6. RESOLUTION 6 – APPROVAL FOR DIRECTOR TO PARTICIPATE IN PLACEMENT – PETER BEWICK

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, for the purposes of section 195(4) and section 208 of the Corporations Act, Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue up to 393,209 Placement Shares to Peter Bewick (or his nominee) on the terms and conditions set out in the Explanatory Statement.”

A voting exclusion statement and voting prohibition statement apply to this Resolution. Please see below.

7. RESOLUTION 7 – APPROVAL FOR DIRECTOR TO PARTICIPATE IN PLACEMENT – JUSTIN OSBORNE

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, for the purposes of section 195(4) and section 208 of the Corporations Act, Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue up to 500,000 Placement Shares to Justin Osborne (or his nominee) on the terms and conditions set out in the Explanatory Statement.”

A voting exclusion statement and voting prohibition statement apply to this Resolution. Please see below.

Dated: 24 August 2026

By order of the Board



**Dan Travers
Company Secretary**

Voting Prohibition Statements

Resolutions 4 to 7 – Approval for related party participation in Placement	In accordance with section 224 of the Corporations Act, a vote on Resolutions 4 to 7 must not be cast (in any capacity) by or on behalf of a related party of the Company to whom the Resolution would permit a financial benefit to be given, or an associate of such a related party (Excluded Party). However, the above prohibition does not apply if the vote is cast by a person as proxy appointed by writing that specifies how the proxy is to vote on the Resolution and it is not cast on behalf of an Excluded Party.
---	--

Voting Exclusion Statements

In accordance with Listing Rule 14.11, the Company will disregard any votes cast in favour of the Resolution set out below by or on behalf of the following persons:

Resolution 1 – Ratification of prior issue of Shares	A person who participated in the issue or is a counterparty to the agreement being approved (namely the Unrelated Participants) or an associate (as defined in the Listing Rules) of that person or those persons.
Resolution 2 – Ratification of prior issue of Shares	A person who participated in the issue or is a counterparty to the agreement being approved (namely the Unrelated Participants) or an associate (as defined in the Listing Rules) of that person or those persons.
Resolution 3 – Approval of the Issue of Lead Manager Options	A person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate (as defined in the Listing Rules) of that person or those persons.
Resolution 4 – Approval for Director to Participate in Placement – Will Robinson	Mr Will Robinson (or his nominee) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate (as defined in the Listing Rules) of that person or those persons.
Resolution 5 – Approval for Director to Participate in Placement – Philip Crutchfield	Mr Philip Crutchfield (or his nominee) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate (as defined in the Listing Rules) of that person or those persons.
Resolution 6 – Approval for Director to Participate in Placement – Peter Bewick	Mr Peter Bewick (or his nominee) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate (as defined in the Listing Rules) of that person or those persons.
Resolution 7 – Approval for Director to Participate in Placement – Justin Osborne	Mr Justin Osborne (or his nominee) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate (as defined in the Listing Rules) of that person or those persons.

However, this does not apply to a vote cast in favour of the Resolution by:

- (a) a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the proxy or attorney to vote on the Resolution in that way; or
- (b) the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or

- (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
 - (ii) the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

VOTING

All Resolutions shall be conducted by poll.

Voting by proxy

To vote by proxy, please complete and sign the enclosed Proxy Form and return by the time and in accordance with the instructions set out on the Proxy Form.

Your Proxy Form must be received by 8:30am (WST) on Saturday, 10 October 2026, being not later than 48 hours before the commencement of the Meeting. Any Proxy Form received after that time will not be valid for the scheduled Meeting.

In accordance with section 249L of the Corporations Act, Shareholders are advised that:

- each Shareholder has a right to appoint a proxy;
- the proxy need not be a Shareholder of the Company; and
- a Shareholder who is entitled to cast two (2) or more votes may appoint two (2) proxies and may specify the proportion or number of votes each proxy is appointed to exercise. If the Shareholder appoints two (2) proxies and the appointment does not specify the proportion or number of the Shareholder's votes, then in accordance with section 249X(3) of the Corporations Act, each proxy may exercise one-half of the votes.

Shareholders and their proxies should be aware that:

- if proxy holders vote, they must cast all directed proxies as directed; and
- any directed proxies which are not voted will automatically default to the Chair, who must vote the proxies as directed.

Voting in person

To vote in person, attend the Meeting at the time, date and place set out above.

You may still attend the Meeting and vote in person even if you have appointed a proxy. If you have previously submitted a Proxy Form, your attendance will not revoke your proxy appointment unless you actually vote at the Meeting for which the proxy is proposed to be used, in which case, the proxy's appointment is deemed to be revoked with respect to voting on that Resolution.

Please bring your personalised Proxy Form with you as it will help to register your attendance at the Meeting. If you do not bring your Proxy Form, you can still attend the Meeting but representatives from the Company will need to verify your identity.

Voting by a corporation

A body corporate that is a Shareholder or which has been appointed as a proxy, may appoint an individual to act as its representative at the Meeting. The appointment must comply with the requirements of section 250D of the Corporations Act. The representative should bring to the Annual General Meeting evidence of their appointment, including any authority under which it is signed, unless it has previously been given to the Company.

Should you wish to discuss the matters in this Notice of Meeting please do not hesitate to contact the Company Secretary on +61 8 9486 9455.

EXPLANATORY STATEMENT

This Explanatory Statement has been prepared to provide information which the Directors believe to be material to Shareholders in deciding whether or not to pass the Resolutions.

The Directors recommend Shareholders read this Explanatory Statement (which forms part of the Notice of Meeting) in full before making any decision in relation to the Resolutions. If you have any questions regarding the matters set out in this Explanatory Statement or the Notice of Meeting, please contact your accountant, solicitor or other professional adviser.

Terms used in this Notice of Meeting have defined meanings which are explained in the Glossary appearing at the end of this Explanatory Statement.

1. BACKGROUND TO RESOLUTIONS 1 TO 7

1.1 Overview

On 17 August 2026, the Company announced that it had received firm commitments from a number of unrelated sophisticated, professional and experienced investors to subscribe for a total of 49,575,892 fully paid ordinary shares in the Company at an issue price of \$0.16 per share (**Placement Shares**) to raise up to \$7.9 million (before costs) (**Placement**).

Of the 49,575,892 Placement Shares issued to unrelated parties of the Company (**Unrelated Participants**) under the Placement, 29,745,535 were issued out of the Company's then (i.e. as at 17 August 2026) available Listing Rule 7.1 placement capacity and 19,830,357 were issued out of the Company's then available Listing Rule 7.1A placement capacity. Gold Fields Limited (**Gold Fields**), Vault Minerals Limited (ACN 068 647 610) (**Vault**) and the Auralandia Group (defined in the Glossary below), who are existing Shareholders of the Company, subscribed for 9,167,500, 3,750,000 and 2,968,750 Placement Shares under the Placement, respectively.

In addition, and subject to Shareholder approval, Directors, Will Robinson, Philip Crutchfield, Peter Bewick and Justin Osborne, have applied for a further 2,005,709 Placement Shares, for an aggregate of \$320,913.

The Placement price of \$0.16 per Placement Share represented a 10.2% discount to the 15-day volume weighted average price as at 12 August 2026 (being the last trading day prior to the announcement of the Placement).

On 24 August 2026, the Company issued 49,575,892 Placement Shares at an issue price of \$0.16 per Placement Share to Unrelated Participants under its Listing Rule 7.1 and 7.1A placement capacity.

Funds raised from the Placement were and will be applied towards exploration programs across the Company's 100% owned Day Dawn Gold Project, Venus Gold Project, West Tanami Project and Cue regional prospects, alongside working capital and costs of the Placement.

1.2 Joint Lead Managers

The Company engaged the services of Argonaut Securities Pty Limited (ACN 108 330 650) (**Argonaut**) and Chieftain Corporate Pty Ltd (ACN 697 675 451) (**Chieftain**) to act as joint lead managers (**Joint Lead Managers**) to the Placement. The material terms of the Joint Lead Managers mandate are as follows:

- (a) In consideration for their services, the Company paid the Joint Lead Managers fees as follows:
 - (i) 2% management fee on the funds raised under the Placement;

- (ii) 3% selling fee on the funds raised under the Placement (excluding funds raised from Gold Fields and Vault prior to the launch of the Placement); and
 - (iii) the Company will issue, subject to Shareholder approval, the Joint Lead Managers (and/or their nominees), in their respective proportions (being 50:50), 1 million unlisted options in the Company, with an exercise price of \$0.30 and an expiry date of 24 months from the date of issue (**Lead Manager Options**).
- (b) The Company agrees to reimburse the Joint Lead Managers for all reasonable out-of-pocket expenses (including any applicable GST) incurred and claimed by the Joint Lead Managers in connection with the Joint Lead Manager Mandate and the Placement.
 - (c) The Joint Lead Managers will pay a selling fee of 4% to Cygnet Capital Pty Ltd (ACN 103 488 606) on any allocation made to its allocated accounts out of their fees (as set out above).

Other than as noted above, the Joint Lead Manager Mandate otherwise contains terms and conditions which are considered standard for an agreement of its kind (including representations, warranties and confidentiality provisions).

1.3 Summary of Resolutions

The Company is seeking Shareholder approval for the following Resolutions relating to the Placement:

- (a) **Resolution 1** – ratification of 29,745,535 Placement Shares issued under the Company's Listing Rule 7.1 Capacity;
- (b) **Resolution 2** – ratification of 19,830,357 Placement Shares issued under the Company's Listing Rule 7.1A Capacity;
- (c) **Resolution 3** – approval for the issue of 1,000,000 Lead Manager Options to the Joint Lead Managers;
- (d) **Resolution 4** – approval to issue 300,000 Placement Shares to Mr Will Robinson for his Placement Participation;
- (e) **Resolution 5** – approval to issue 812,500 Placement Shares to Mr Philip Crutchfield for his Placement Participation;
- (f) **Resolution 6** – approval to issue 393,209 Placement Shares to Mr Peter Bewick for his Placement Participation; and
- (g) **Resolution 7** – approval to issue 500,000 Placement Shares to Mr Justin Osborne for his Placement Participation.

2. RESOLUTIONS 1 AND 2 – RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES – LISTING RULES 7.1 AND 7.1A

2.1 General

As set out in Section 1.1 above, on 24 August 2026, the Company issued 49,575,892 Placement Shares to the Unrelated Participants.

29,745,535 Placement Shares were issued pursuant to the Company's capacity under Listing Rule 7.1 (being, the subject of Resolution 1) and 19,830,357 Placement Shares (being, the subject of Resolution 2) were issued pursuant to the Company's 7.1A

mandate, which was approved by Shareholders at the Company's annual general meeting held on 27 November 2025 (**Annual General Meeting**).

The issue of the Placement Shares did not breach Listing Rule 7.1 at the time of issue.

2.2 Listing Rules 7.1 and 7.1A

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of equity securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of that 12 month period.

Under Listing Rule 7.1A however, an eligible entity can seek approval from its members, by way of a special resolution passed at its annual general meeting, to increase this 15% limit by an extra 10% to 25%.

The Company obtained approval to increase its limit to 25% at the Annual General Meeting.

The issue of the Placement Shares does not fit within any of the exceptions set out in Listing Rule 7.2 and, as it has not yet been approved by Shareholders, it effectively uses up part of the 25% limit in Listing Rules 7.1 and 7.1A, reducing the Company's capacity to issue further equity securities without Shareholder approval under Listing Rule 7.1 and 7.1A for the 12 month period following the date of issue of the Placement Shares under the Placement.

2.3 Listing Rule 7.4

Listing Rule 7.4 allows the shareholders of a listed company to approve an issue of equity securities after it has been made or agreed to be made. If they do, the issue is taken to have been approved under Listing Rules 7.1 or 7.1A (as appropriate) and so does not reduce the company's capacity to issue further equity securities without shareholder approval under that rule.

The Company wishes to retain as much flexibility as possible to issue additional equity securities in the future without having to obtain Shareholder approval. Accordingly, the Company is seeking Shareholder ratification pursuant to Listing Rule 7.4 for the issue of the Placement Shares.

To this end, Resolution 1 and Resolution 2 seek Shareholder ratification pursuant to Listing Rule 7.4 for the issue of the 49,575,892 Placement Shares referred to above.

2.4 Technical information required by Listing Rule 14.1A

If Resolution 1 and Resolution 2 are passed, the Placement Shares will be excluded in calculating the Company's combined 25% limit in Listing Rules 7.1 and 7.1A, effectively increasing the number of equity securities the Company can issue without Shareholder approval over the 12 month period following the date of issue of the Placement Shares.

If Resolution 1 and Resolution 2 are not passed, the Placement Shares will be included in calculating the Company's combined 25% limit in Listing Rules 7.1 and 7.1A, effectively decreasing the number of equity securities the Company can issue without Shareholder approval over the 12 month period following the date of issue of the Placement Shares.

2.5 Technical information required by Listing Rule 7.5

Pursuant to and in accordance with Listing Rule 7.5, the following information is provided in relation to Resolution 1 and Resolution 2:

- (a) the Placement Shares issued under the Placement were issued to sophisticated, professional and experienced investors who were either existing Shareholders

of the Company or clients of the Joint Lead Managers, none of whom are related parties of the Company. In seeking to procure commitments under the Placement, the Joint Lead Managers identified investors through a bookbuild process, which involved the Joint Lead Managers seeking expressions of interest to participate in the capital raising from non-related parties of the Company;

- (b) in accordance with paragraph 7.4 of ASX Guidance Note 21, the Company confirms that, other than Gold Fields (who was issued 9,167,500 Placement Shares), Vault (who was issued 3,750,000 Placement Shares) and the Auralandia Group (who was issued 2,968,750 Placement Shares) pursuant to the Placement on 24 August 2026), and who were substantial Shareholders in the Company before the Placement, none of the recipients were:
 - (i) related parties of the Company, members of the Company's Key Management Personnel, substantial shareholders of the Company, advisers of the Company or an associate of any of these parties; and
 - (ii) issued more than 1% of the issued capital of the Company;
- (c) 49,575,892 Placement Shares were issued on the following basis:
 - (i) 29,745,535 Placement Shares issued pursuant to Listing Rule 7.1 (ratification of which is sought under Resolution 1); and
 - (ii) 19,830,357 Placement Shares issued pursuant to Listing Rule 7.1A (ratification of which is sought under Resolution 2);
- (d) the Placement Shares issued were all fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares;
- (e) the Placement Shares were issued on 24 August 2026;
- (f) the issue price was \$0.16 per Placement Share. The Company has not and will not receive any other consideration for the issue of the Placement Shares the subject of Resolution 1 and Resolution 2;
- (g) the purpose of the issue of the Placement Shares is set out in Section 1.1 above;
- (h) the Placement Shares were not issued under an agreement; and
- (i) a voting exclusion statement is included in respect of Resolution 1 and Resolution 2 of the Notice.

2.6 Additional information

- (a) As stated in Section 2.5(a) above, the Placement Shares issued under the Placement were issued to sophisticated, professional and experienced investors who were either existing Shareholders of the Company or clients of the Joint Lead Managers, none of whom are related parties of the Company. In seeking to procure commitments under the Placement, the Joint Lead Managers identified investors through a bookbuild process, which involved the Joint Lead Managers seeking expressions of interest to participate in the capital raising from non-related parties of the Company. The final issue price of the Placement Shares was determined by the Joint Lead Managers, after taking into account the demand for the Company's shares and the prevailing share price. The Directors of the Company sought to issue shares pursuant to the Placement at a price as close as possible to the prevailing market price so as not to disadvantage existing Shareholders in the Company, and considered the achieved Placement issue price to be consistent with that goal.

- (b) No alternative options to the Placement were considered by the Company as the Company considered the Placement to be in the best interests of Shareholders.
- (c) The Company did not seek or receive any expert advice in relation to the Placement beyond that provided by the Joint Lead Managers as to the appropriate pricing of the Placement Shares and HopgoodGanim Lawyers as to compliance with the Company's obligations under the Corporations Act and Listing Rules.

2.7 Directors' Recommendation

All of the Directors recommend that Shareholders vote in favour of Resolution 1 and Resolution 2.

3. RESOLUTION 3 – APPROVAL FOR THE ISSUE OF LEAD MANAGER OPTIONS

Pursuant to the terms of engagement of the Joint Lead Managers to the Placement (as described in Section 1.2 above, the Company has agreed to issue the Joint Lead Managers (or their nominee(s)) 1,000,000 options, subject to Shareholder approval (**Lead Manager Options**). The Lead Manager Options are to be issued as part consideration for the services provided by the Joint Lead Managers pursuant to the Joint Lead Manager Mandate.

The Company is seeking Shareholder approval for the purposes of Listing Rule 7.1 for the issue of 1,000,000 Lead Manager Options.

3.1 Listing Rule 7.1

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of equity securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary shares it had on issue at the start of that period.

The proposed issue of the Lead Manager Options falls within exception 17 of Listing Rule 7.2.

Listing Rule 7.2 provides a number of exceptions to Listing Rule 7.1 and Listing Rule 7.1A. Specifically, exception 17 of Listing Rule 7.2 provides for an agreement to issue equity securities that is conditional on the shareholders of an entity's ordinary securities approving the issue under Listing Rule 7.1 before the issue is made. If an entity relies upon this exception, it must not issue the equity securities without such approval.

The Company therefore requires the approval of Shareholders under Listing Rule 7.1.

3.2 Technical information required by Listing Rule 14.1A

If Resolution 3 is passed, it will permit the Company to proceed to issue 1,000,000 Lead Manager Options. Further, the Lead Manager Options issued will be excluded in calculating the Company's combined 25% limit in Listing Rules 7.1 and 7.1A, effectively increasing the number of equity securities the Company can issue without Shareholder approval over the 12 month period following the date of issue of the Lead Manager Options.

If Resolution 3 is not passed, the Company will not be able to proceed with the issue of the 1,000,000 Lead Manager Options and the Company may have to consider compensating the Joint Lead Managers by alternative means.

3.3 Technical information required by Listing Rule 7.5

Pursuant to and in accordance with Listing Rule 7.5, the following information is provided in relation to Resolution 3:

- (a) the proposed Lead Manager Options will be issued to Chieftain and Argonaut, as Joint Lead Managers to the Placement, who are not related parties of the Company;
- (b) a maximum of 1,000,000 Lead Manager Options will be issued pursuant to this approval. The Joint Lead Managers will receive 500,000 Lead Manager Options each;
- (c) the Lead Manager Options will be issued on the terms and conditions set out in Schedule 1;
- (d) the Lead Manager Options will be issued no later than 3 months after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules);
- (e) the Lead Manager Options will be issued for a nominal subscription price of \$0.00001 per option, in consideration for Joint Lead Manager services provided by the Joint Lead Managers under the Joint Lead Manager Mandate. The Company has not and will not receive any other consideration for the issue of the Lead Manager Options (other than in respect of funds received on exercise of the Lead Manager Options);
- (f) the purpose of the issue is to satisfy the Company's obligations under the Joint Lead Manager Mandate;
- (g) the Lead Manager Options are being issued under the Joint Lead Manager Mandate, a summary of which is set out in Section 1.2; and
- (h) a voting exclusion statement is included in respect of Resolution 3 of the Notice.

3.4 Directors' Recommendation

All of the Directors recommend that Shareholders vote in favour of Resolution 3.

4. RESOLUTIONS 4 TO 7 – PARTICIPATION IN CAPITAL RAISING BY DIRECTORS

4.1 General

As set out in Section 1.1 above, the Company has agreed, subject to obtaining Shareholder approval, to issue an aggregate of 2,005,709 Placement Shares to Directors of the Company, Messrs Will Robinson, Philip Crutchfield, Peter Bewick and Justin Osborne (or their respective nominees) (**Participating Directors**). Each Director wishes to participate in the Placement on the same terms as the Unrelated Participants under the Placement (the subject of Resolutions 1 and 2) (**Director Participation**).

Accordingly, Resolutions 4 to 7 seek Shareholder approval for the issue of a total of 2,005,709 Placement Shares (**Director Shares**) to the Participating Directors (or their respective nominees), as a result of the Director Participation on the terms set out below.

4.2 Chapter 2E of the Corporations Act

Pursuant to Chapter 2E of the Corporations Act, for a public company, or an entity that the public company controls, to give a financial benefit to a related party of the public company, the public company or entity must:

- (a) obtain the approval of the public company's members in the manner set out in sections 217 to 227 of the Corporations Act; and
- (b) give the benefit within 15 months following such approval,

unless the giving of the financial benefit falls within an exception set out in sections 210 to 216 of the Corporations Act.

The Director Participation will result in the issue of the Director Shares to the Participating Directors which constitutes giving a financial benefit and the Participating Directors are each related parties of the Company by virtue of being Directors.

As the Director Shares are proposed to be issued to each of the Company's four Directors, the Directors are unable to form a quorum to consider whether one of the exceptions set out in sections 210 to 216 of the Corporations Act applies to the issue of the Director Shares to the Participating Directors. Accordingly, the Directors have determined that Shareholders should have the opportunity to vote on the giving of the financial benefit pursuant to section 208 and 195(4) of the Corporations Act under each of Resolutions 4 to 7.

4.3 Listing Rule 10.11

Listing Rule 10.11 provides that, unless one of the exceptions in Listing Rule 10.12 applies, a listed company must not issue or agree to issue equity securities to:

- 10.11.1 a related party;
- 10.11.2 a person who is, or was at any time in the 6 months before the issue or agreement, a substantial (30%+) holder in the company;
- 10.11.3 a person who is, or was at any time in the 6 months before the issue or agreement, a substantial (10%+) holder in the company and who has nominated a director to the board of the company pursuant to a relevant agreement which gives them a right or expectation to do so;
- 10.11.4 an associate of a person referred to in Listing Rules 10.11.1 to 10.11.3; or
- 10.11.5 a person whose relationship with the company or a person referred to in Listing Rules 10.11.1 to 10.11.4 is such that, in ASX's opinion, the issue or agreement should be approved by its shareholders,

unless it obtains the approval of its shareholders.

If Shareholder approval is given under Listing Rule 10.11, Listing Rule 7.2, Exception 14 provides that Shareholder approval is not required under Listing Rule 7.1.

The Director Participation falls within Listing Rule 10.11.1 (and if the Director Shares are issued to a nominee who is an associate of the relevant Director, the nominee will fall within Listing Rule 10.11.4 by virtue of being an associate of a Director) and does not fall within any of the exceptions in Listing Rule 10.12. It therefore requires the approval of the Company's Shareholders under Listing Rule 10.11.

Resolutions 4 to 7 seek the required Shareholder approval for the Director Participation under and for the purposes of Listing Rule 10.11.

4.4 Technical information required by Listing Rule 14.1A

If any or all of Resolutions 4 to 7 are passed, the Company will be able to proceed with the issue of the Director Shares to the Participating Directors in respect of whom the relevant Resolution(s) is passed within one month after the date of the Meeting (or such later date as permitted by any ASX waiver or modification of the Listing Rules) and will raise additional funds which will be used in the manner set out in Section 1.1 above.

As approval pursuant to Listing Rule 7.1 is not required for the issue of the Director Shares in respect of the Director Participation (because approval is being obtained under Listing

Rule 10.11), the issue of the Director Shares will not use up any of the Company's 15% annual placement capacity.

If any or all of Resolutions 4 to 7 are not passed, the Company will not be able to proceed with the issue of the Director Shares under the Director Participation to the Participating Directors in respect of whom the relevant Resolutions are not passed, and no further funds will be raised in respect of the Placement.

4.5 Technical Information required by Listing Rule 10.13 and section 219 of the Corporations Act

Pursuant to and in accordance with Listing Rule 10.13 and section 219 of the Corporations Act, the following information is provided in relation to Resolutions 4 to 7:

- (a) the Director Shares will be issued to the Participating Directors and will be comprised of the following:
 - (i) 300,000 Director Shares, valued at \$48,000, will be issued to Mr Will Robinson (or his nominee) pursuant to Resolution 4;
 - (ii) 812,500 Director Shares, valued at \$130,000, will be issued to Mr Philip Crutchfield (or his nominee) pursuant to Resolution 5;
 - (iii) 393,209 Director Shares, valued at \$62,913, will be issued to Mr Peter Bewick (or his nominee) pursuant to Resolution 6; and
 - (iv) 500,000 Director Shares, valued at \$80,000, will be issued to Mr Justin Osborne (or his nominee) pursuant to Resolution 7,

each of whom falls within the category set out in Listing Rule 10.11.1 by virtue of the Participating Directors each being a Director. If the Director Shares are issued to a nominee who is an associate of the relevant Director, the nominee will fall within the category set out in Listing Rule 10.11.4, by virtue of the nominee being an associate (as defined in the Listing Rules) of a Director;

- (b) the maximum number of Director Shares to be issued is 2,005,709 (being the nature of financial benefit proposed to be given) and will be allocated in the proportions set out above;
- (c) the Director Shares will be fully paid ordinary shares in the capital of the Company and be issued on the same terms and conditions as the Company's existing Shares on issue;
- (d) the Director Shares will be issued no later than 1 month after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules) and it is intended that issue of the Director Shares will occur on the same date;
- (e) the purpose of the issue of the Director Shares is to allow the Participating Directors to participate in the Placement and the funds raised will be put towards the activities set out in Section 1.1;
- (f) the Participating Directors will participate in the Placement on the same terms as the Unrelated Participants (being institutional, professional and sophisticated investors who take part in the Placement). Consequently, the number of Director Shares to be issued to the Participating Directors has been determined based upon the terms of the Placement Shares to be issued to the institutional, professional and sophisticated investors who took part in the Placement;

- (g) the Company does not consider that there are any significant opportunity costs to the Company or benefits forgone by the Company in issuing the Director Shares to the Participating Directors upon the terms proposed;
- (h) the issue of the Directors Shares to the Participating Directors is not intended to be conferred by way of remuneration or incentive. However, in the interests of full and proper disclosure, the total remuneration package of each Participating Director of the Company in the previous financial year and the proposed total remuneration package for the current financial year are set out below:

Related Party	Current Financial Year Ended 30 June 2026¹	Previous Financial Year Ended 30 June 2025^{1,4}
Will Robinson	\$67,606 ²	\$77,999
Philip Crutchfield	\$67,606 ²	\$77,999
Peter Bewick	\$477,877 ³	\$379,275
Justin Osborne	\$67,606 ²	\$77,999

Notes:

- Amounts include total fixed remuneration (TFR) and value of securities received as remuneration during the period, securities yet to be issued have not been included.
 - Comprising Director's TFR of \$56,000 (inclusive of superannuation contributions) and incentive options (approved at the Annual General Meeting) valued at \$11,606.
 - Comprising Director's TFR of \$361,977 (inclusive of superannuation contributions), short term incentive bonus for the 12 months ended 31 December 2025 of \$22,844 and incentive options (approved at the Annual General Meeting) valued at \$94,300.
 - Refer to the remuneration report for the financial year ended 30 June 2025 included in the Company's 2025 Annual Financial Report.
- (i) the issue price of the Director Shares will be \$0.16 per Director Share, being the issue price of the Placement Shares issued to Unrelated Participants under the Placement. The Company will not receive any other consideration in respect of the issue of the Director Shares in respect of the Director Participation;
- (j) the Director Shares in respect of the Director Participation are not being issued under an agreement;
- (k) the Director Shares are not being issued under, or to fund, a reverse takeover;
- (l) a voting exclusion statement is included in respect of each of Resolutions 4 to 7 of the Notice;
- (m) the relevant interests of the Participating Directors in securities of the Company are set out below:

As at the date of this Notice

Related Party	Shares¹	Options	Undiluted	Fully Diluted²
Will Robinson	6,602,357	1,753,231	2.7%	3.2%
Philip Crutchfield	3,711,012	2,253,231	1.5%	2.2%
Peter Bewick	4,806,791	7,367,010	1.9%	4.6%
Justin Osborne	1,425,000	1,753,231	0.6%	1.2%

Post issue of Shares to Participating Directors

Related Party	Shares¹	Options	Undiluted	Fully Diluted²
Will Robinson	6,902,357	1,753,231	2.8%	3.2%
Philip Crutchfield	4,523,512	2,253,231	1.8%	2.5%
Peter Bewick	5,200,000	7,367,010	2.1%	4.7%
Justin Osborne	1,925,000	1,753,231	0.8%	1.4%

Notes:

1. Fully paid ordinary shares in the capital of the Company (ASX: HMG).
 2. Fully diluted interest is calculated assuming all options on issue are exercised.
- (n) if the Director Shares are issued this will increase the number of Shares on issue from 247,879,463 (being the total number of shares on issue after completion of the issue of all Placement Shares to Unrelated Participants) to 249,885,172 (assuming that no further shares are issued and no options are exercised) with the effect that the shareholding of existing Shareholders would be diluted by an aggregate of 0.8%;
- (o) the trading history of the Shares on ASX in the 12 months before the date of this Notice is set out below:

	Price	Date
Highest	\$0.22	3 August 2026
Lowest	\$0.05	19 August 2025
Last	\$0.26	21 August 2026

- (p) the Company did not seek or receive any expert advice in relation to the Participating Directors' participation;
- (q) as noted above, the Participating Directors will participate in the Placement on the same terms as Unrelated Participants and the issue price of the Director Shares will be \$0.16 per Director Share, being same price as the Placement Shares issued to Unrelated Participants. As at market close on 21 August 2026 (being the last day on which trades in the Company's shares occurred prior to the date of this Notice), the price of the Company's Share was \$0.26 which is \$0.10 per Share higher than the price of the Director Shares to be issued to the Participating Directors. If this difference is maintained up to the date the Director Shares are issued to the Participating Directors, they will each receive a benefit of \$0.10 per Director Share; and
- (r) the Board is not aware of any other information that is reasonably required by Shareholders to allow them to decide whether it is in the best interests of the Company to pass Resolutions 4 to 7.

4.6 Director Recommendation

Each Participating Director has a material personal interest in the outcome of Resolutions 4 to 7 on the basis that all of the Participating Directors (or their nominees), are to be issued the Director Shares should Resolutions 4 to 7 be passed.

For this reason, the Participating Directors do not believe that it is appropriate to make a recommendation on Resolutions 4 to 7 of this Notice.

GLOSSARY

\$ means Australian dollars.

Annual General Meeting has the meaning given in Section 2.1.

Argonaut means Argonaut Securities Pty Limited (ACN 108 330 650).

ASX means ASX Limited (ACN 008 624 691) or the financial market operated by ASX Limited, as the context requires.

Auralandia Group means Auralandia Pty Ltd (ACN 004 913 884), Bass Strait Group Pty Ltd (ACN 005 512 434), Hawkestone Resources Pty Ltd (ACN 168 122 263) and Westminex Pty Ltd (ACN 009 240 420).

Board means the current board of directors of the Company.

Business Day means Monday to Friday inclusive, except New Year's Day, Good Friday, Easter Monday, Christmas Day, Boxing Day, and any other day that ASX declares is not a business day.

Chair means the chair of the Meeting.

Chieftain means Chieftain Corporate Pty Ltd (ACN 697 675 451).

Company means Hamelin Gold Limited (ACN 650 439 580).

Corporations Act means the *Corporations Act 2001* (Cth).

Directors means the current directors of the Company.

Director Participation has the meaning given in Section 4.1.

Director Shares has the meaning given in Section 4.1.

Explanatory Statement means the explanatory statement accompanying the Notice.

General Meeting or **Meeting** means the meeting convened by the Notice.

Gold Fields means Gold Fields Limited.

Joint Lead Manager Mandate means the mandate entered into between the Company and the Joint Lead Managers dated 12 August 2026.

Joint Lead Managers means Argonaut and Chieftain.

Key Management Personnel has the same meaning as in the accounting standards issued by the Australian Accounting Standards Board and means those persons having authority and responsibility for planning, directing and controlling the activities of the Company, or if the Company is part of a consolidated entity, of the consolidated entity, directly or indirectly, including any director (whether executive or otherwise) of the Company, or if the Company is part of a consolidated entity, of an entity within the consolidated group.

Lead Manager Options means the options proposed to be issued to the Joint Lead Managers pursuant to Resolution 3.

Listing Rules means the Listing Rules of ASX.

Notice or **Notice of Meeting** means this notice of meeting including the Explanatory Statement and the Proxy Form.

Participating Directors means Directors, Messrs Will Robinson, Philip Crutchfield, Peter Bewick and Justin Osborne.

Placement has the meaning given in Section 1.1.

Placement Shares has the meaning given in Section 1.1.

Proxy Form means the proxy form accompanying the Notice.

Resolutions means the resolutions set out in the Notice, or any one of them, as the context requires.

Section means a section of the Explanatory Statement.

Share means a fully paid ordinary share in the capital of the Company.

Shareholder means a registered holder of a Share.

Unrelated Participants means the unrelated participants under the Placement, being various institutional, professional and sophisticated investors arranged by the Joint Lead Managers.

Vault means Vault Minerals Limited (ACN 068 647 610).

VWAP means the volume weighted average market price.

WST means Western Standard Time as observed in Perth, Western Australia.

SCHEDULE 1 TERMS AND CONDITIONS OF LEAD MANAGER OPTIONS

A summary of the terms and conditions of the Options is as follows:

- a) **Entitlement:** Each Option entitles the holder to subscribe for one Share upon exercise of the Option.
- b) **Exercise Price:** The amount payable upon exercise of each Option will be \$0.30 (**Exercise Price**).
- c) **Expiry Date:** Each Option will expire at 5:00pm (WST) on the day that is 24 months from the date of issue (**Expiry Date**). An Option not exercised before the Expiry Date will automatically lapse on the Expiry Date.
- d) **Exercise Period:** The Options are exercisable at any time and from time to time on or prior to the Expiry Date (**Exercise Period**).
- e) **Notice of Exercise:** The Options may be exercised during the Exercise Period by notice in writing to the Company in the manner specified on the Option certificate or as otherwise agreed with the Company (**Notice of Exercise**) and payment of the Exercise Price for each Option being exercised in Australian currency by electronic funds transfer or other means of payment acceptable to the Company.
- f) **Exercise Date:** A Notice of Exercise is only effective on and from the later of the date of receipt of the Notice of Exercise and the date of receipt of the payment of the Exercise Price for each Option being exercised in cleared funds (**Exercise Date**).
- g) **Timing of issue of Shares on exercise:** Within 5 Business Days after the Exercise Date, the Company will:
 - i. allot and issue the number of Shares required under these terms and conditions in respect of the number of Options specified in the Notice of Exercise and for which cleared funds have been received by the Company;
 - ii. give ASX a notice that complies with section 708A(5)(e) of the Corporations Act; and
 - iii. if admitted to the official list of ASX at the time, apply for official quotation on ASX of Shares issued pursuant to the exercise of the Options.
 - iv. If the Company is unable to deliver a notice under paragraph (g)(ii) or such a notice for any reason is not effective to ensure that an offer for sale of the Shares does not require disclosure to investors, the Company must immediately lodge with ASIC a disclosure document prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors.
- h) **Shares issued on exercise:** Shares issued on exercise of the Options rank equally with the then issued Shares of the Company.
- i) **Quotation of Shares issued on exercise:** If admitted to the official list of ASX at the time, application will be made by the Company to ASX for quotation of the Shares issued upon the exercise of the Options.
- j) **Reconstruction of capital:** If at any time the issued capital of the Company is reconstructed, all rights of the holder are to be changed in a manner consistent with the Corporations Act and the Listing Rules at the time of the reconstruction.
- k) **Participation in new issues:** There are no participation rights or entitlements inherent in the Options and holders will not be entitled to participate in new issues of capital offered to Shareholders during the currency of the Options without exercising the Options.
- l) **Quotation of the Options:** The Company will not apply for quotation of the Options on the ASX.
- m) **Transferability of the Options:** The Options are transferable at the election of the holder subject to any restriction or escrow arrangements imposed by the ASX or under applicable Australian securities law.

Proxy Voting Form

If you are attending the Meeting in person, please bring this with you for Securityholder registration.

Your proxy voting instruction must be received by **8:30am (AWST) on Saturday, 10 October 2026**, being **not later than 48 hours** before the commencement of the Meeting. Any Proxy Voting instructions received after that time will not be valid for the scheduled Meeting.

SUBMIT YOUR PROXY

Complete the form overleaf in accordance with the instructions set out below.

YOUR NAME AND ADDRESS

The name and address shown above is as it appears on the Company's share register. If this information is incorrect, and you have an Issuer Sponsored holding, you can update your address through the investor portal: <https://investor.automic.com.au/#/home> Shareholders sponsored by a broker should advise their broker of any changes.

STEP 1 - APPOINT A PROXY

If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that Individual or body corporate. A proxy need not be a Shareholder of the Company. Otherwise if you leave this box blank, the Chair of the Meeting will be appointed as your proxy by default.

DEFAULT TO THE CHAIR OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote these proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Voting Form, including where the Resolutions are connected directly or indirectly with the remuneration of Key Management Personnel.

STEP 2 - VOTES ON ITEMS OF BUSINESS

You may direct your proxy how to vote by marking one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF SECOND PROXY

You may appoint up to two proxies. If you appoint two proxies, you should complete two separate Proxy Voting Forms and specify the percentage or number each proxy may exercise. If you do not specify a percentage or number, each proxy may exercise half the votes. You must return both Proxy Voting Forms together. If you require an additional Proxy Voting Form, contact Automic Registry Services.

SIGNING INSTRUCTIONS

Individual: Where the holding is in one name, the Shareholder must sign.

Joint holding: Where the holding is in more than one name, all Shareholders should sign.

Power of attorney: If you have not already lodged the power of attorney with the registry, please attach a certified photocopy of the power of attorney to this Proxy Voting Form when you return it.

Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you.

Email Address: Please provide your email address in the space provided.

By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible) such as a Notice of Meeting, Proxy Voting Form and Annual Report via email.

CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate 'Appointment of Corporate Representative' should be produced prior to admission. A form may be obtained from the Company's share registry online at <https://automicgroup.com.au>.

Lodging your Proxy Voting Form:

Online

Use your computer or smartphone to appoint a proxy at <https://portal.automic.com.au/investor/home> or scan the QR code below using your smartphone

Login & Click on 'Meetings'. Use the Holder Number as shown at the top of this Proxy Voting Form.



BY MAIL:

Automic
GPO Box 5193
Sydney NSW 2001

IN PERSON:

Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

BY EMAIL:

meetings@automicgroup.com.au

BY FACSIMILE:

+61 2 8583 3040

All enquiries to Automic:

WEBSITE:

<https://automicgroup.com.au>

PHONE:

1300 288 664 (Within Australia)
+61 2 9698 5414 (Overseas)

I/We being a Shareholder entitled to attend and vote at the General Meeting of Hamelin Gold Limited, to be held at **8:30am (AWST) on Monday, 12 October 2026 at Suite 2, 1 Alvan Street, Subiaco WA 6008** hereby:

Please note: If you are not appointing the Chair of the Meeting as your proxy, please write in the box provided below the name of the person or body corporate you are appointing as your proxy. If the person so named is absent from the meeting, or if no person is named, the Chair will act on your behalf.

[illegible]

Unless indicated otherwise by marking the “for”, “against” or “abstain” box you will be authorising the Chair to vote in accordance with the Chair’s voting intention.

Where I/we have appointed the Chair as my/our proxy (or where the Chair becomes my/our proxy by default), I/we expressly authorise the Chair to exercise my/our proxy on Resolutions 4, 5, 6 and 7 (except where I/we have indicated a different voting intention below) even though Resolutions 4, 5, 6 and 7 are connected directly or indirectly with the remuneration of a member of the Key Management Personnel, which includes the Chair.

Resolutions	For	Against	Abstain
1 RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES – LISTING RULE 7.1	☐	☐	☐
2 RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES – LISTING RULE 7.1A	☐	☐	☐
3 APPROVAL OF ISSUE OF LEAD MANAGER OPTIONS	☐	☐	☐
4 APPROVAL FOR DIRECTOR TO PARTICIPATE IN PLACEMENT – WILL ROBINSON	☐	☐	☐
5 APPROVAL FOR DIRECTOR TO PARTICIPATE IN PLACEMENT – PHILIP CRUTCHFIELD	☐	☐	☐
6 APPROVAL FOR DIRECTOR TO PARTICIPATE IN PLACEMENT – PETER BEWICK	☐	☐	☐
7 APPROVAL FOR DIRECTOR TO PARTICIPATE IN PLACEMENT – JUSTIN OSBORNE	☐	☐	☐

Please note: If you mark the abstain box for a particular Resolution, you are directing your proxy not to vote on that Resolution and your votes will not be counted in computing the required majority on a poll.

Individual or Securityholder 1	Securityholder 2	Securityholder 3
Sole Director and Sole Company Secretary	Director	Director / Company Secretary

Contact Name:

Email Address:

Contact Daytime Telephone:

Date (DD/MM/YY) / /

By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible).